1. Prostate cancer is the most common noncutaneous malignancy in men in the USA. Screening involves digital rectal exam and PSA testing.
2. Treatment options depend on risk level and include active surveillance for low risk, and surgery or radiation for higher risk. Active surveillance involves regular monitoring to avoid unnecessary treatment.
3. Staging involves biopsy, imaging like MRI, and determines risk level and treatment. Outcomes depend on tumor grade and stage.
diagnosis and outline of management of localized prostate cancer for non-urol...Dr Mayank Mohan Agarwal
This document provides an overview of localized prostate cancer, including:
1. It describes the anatomy of the prostate and surrounding structures.
2. It discusses diagnosis and imaging for prostate cancer including DRE, PSA testing, multiparametric MRI, and prostate biopsy.
3. It covers risk stratification for prostate cancer based on factors like Gleason score, PSA, and tumor stage to determine appropriate management strategies.
Carcinoma prostate is the most common cancer in men. Yet there are unresolved issues. It was thought that serum PSA levels would be diagnostic for this particular cancer. However, it has now been proven beyond doubt that it can be raised in many other conditions.
Dr. Arjun Singh, a 52-year-old male, presented for his annual health checkup. He has a family history of prostate cancer as his father had it. His PSA levels have been monitored every few years and were previously normal, but are now elevated at 4.5 ng/ml. A digital rectal exam found no abnormalities in the prostate. Given his rising PSA and family history, a prostate biopsy was recommended to evaluate for possible prostate cancer.
This document summarizes guidelines for diagnosis and treatment of prostate cancer. It discusses various staging tests including digital rectal exam, PSA levels, and biopsy. For localized disease, active surveillance is recommended for very low risk while radical prostatectomy or radiotherapy are options for low to intermediate risk. For high risk disease, radiotherapy dose escalation to 74-80 Gy is recommended. Brachytherapy or external beam radiotherapy with brachytherapy boost are discussed. Androgen deprivation therapy is indicated for high risk, locally advanced or metastatic disease.
This document discusses transrectal ultrasound (TRUS)-guided prostate biopsy. It begins with an introduction to declining prostate cancer mortality due to early detection programs using prostate-specific antigen (PSA) testing and TRUS-guided biopsy. It then covers the ultrasonographic anatomy of the prostate visible on TRUS, different TRUS biopsy techniques, indications for biopsy, and advanced ultrasound techniques like color and power Doppler that can help identify areas of neovascularity suspicious for cancer. The document provides a comprehensive overview of how TRUS is used to image the prostate and guide systematic biopsies for prostate cancer detection and diagnosis.
Management of prostate cancer involves assessing risk levels based on PSA, Gleason score, and percentage of positive biopsy cores. Treatment options include active surveillance for low risk prostate cancer with potential delayed treatment if cancer progresses. Radical prostatectomy is the gold standard for localized prostate cancer and provides the possibility of cure with minimal side effects when performed by an experienced surgeon. While providing excellent cancer control, radical prostatectomy carries risks of erectile dysfunction and urinary incontinence.
This document discusses recent advances in prostate cancer, including updated screening guidelines, diagnostic tools, biomarkers, staging, and treatments. It provides an overview of prostate cancer epidemiology and risk factors. Screening involves PSA testing and digital rectal exams for men aged 55-69. Multiparametric MRI and MRI-ultrasound fusion biopsies have improved detection of aggressive cancers. Staging involves bone scans, PET scans, and the TNM system. Biomarkers like PSMA and PCA3 are also discussed.
Prostate cancer is the most commonly diagnosed cancer and second leading cause of cancer death among men over 65 in Western countries. Risk factors include increasing age, family history, and diet. Histopathological grading uses the Gleason grading system to determine tumor differentiation and prognosis. Treatment options depend on disease stage and include local therapies like surgery and radiation for early disease, hormone therapy for advanced or metastatic disease, and chemotherapy for hormone-refractory prostate cancer.
diagnosis and outline of management of localized prostate cancer for non-urol...Dr Mayank Mohan Agarwal
This document provides an overview of localized prostate cancer, including:
1. It describes the anatomy of the prostate and surrounding structures.
2. It discusses diagnosis and imaging for prostate cancer including DRE, PSA testing, multiparametric MRI, and prostate biopsy.
3. It covers risk stratification for prostate cancer based on factors like Gleason score, PSA, and tumor stage to determine appropriate management strategies.
Carcinoma prostate is the most common cancer in men. Yet there are unresolved issues. It was thought that serum PSA levels would be diagnostic for this particular cancer. However, it has now been proven beyond doubt that it can be raised in many other conditions.
Dr. Arjun Singh, a 52-year-old male, presented for his annual health checkup. He has a family history of prostate cancer as his father had it. His PSA levels have been monitored every few years and were previously normal, but are now elevated at 4.5 ng/ml. A digital rectal exam found no abnormalities in the prostate. Given his rising PSA and family history, a prostate biopsy was recommended to evaluate for possible prostate cancer.
This document summarizes guidelines for diagnosis and treatment of prostate cancer. It discusses various staging tests including digital rectal exam, PSA levels, and biopsy. For localized disease, active surveillance is recommended for very low risk while radical prostatectomy or radiotherapy are options for low to intermediate risk. For high risk disease, radiotherapy dose escalation to 74-80 Gy is recommended. Brachytherapy or external beam radiotherapy with brachytherapy boost are discussed. Androgen deprivation therapy is indicated for high risk, locally advanced or metastatic disease.
This document discusses transrectal ultrasound (TRUS)-guided prostate biopsy. It begins with an introduction to declining prostate cancer mortality due to early detection programs using prostate-specific antigen (PSA) testing and TRUS-guided biopsy. It then covers the ultrasonographic anatomy of the prostate visible on TRUS, different TRUS biopsy techniques, indications for biopsy, and advanced ultrasound techniques like color and power Doppler that can help identify areas of neovascularity suspicious for cancer. The document provides a comprehensive overview of how TRUS is used to image the prostate and guide systematic biopsies for prostate cancer detection and diagnosis.
Management of prostate cancer involves assessing risk levels based on PSA, Gleason score, and percentage of positive biopsy cores. Treatment options include active surveillance for low risk prostate cancer with potential delayed treatment if cancer progresses. Radical prostatectomy is the gold standard for localized prostate cancer and provides the possibility of cure with minimal side effects when performed by an experienced surgeon. While providing excellent cancer control, radical prostatectomy carries risks of erectile dysfunction and urinary incontinence.
This document discusses recent advances in prostate cancer, including updated screening guidelines, diagnostic tools, biomarkers, staging, and treatments. It provides an overview of prostate cancer epidemiology and risk factors. Screening involves PSA testing and digital rectal exams for men aged 55-69. Multiparametric MRI and MRI-ultrasound fusion biopsies have improved detection of aggressive cancers. Staging involves bone scans, PET scans, and the TNM system. Biomarkers like PSMA and PCA3 are also discussed.
Prostate cancer is the most commonly diagnosed cancer and second leading cause of cancer death among men over 65 in Western countries. Risk factors include increasing age, family history, and diet. Histopathological grading uses the Gleason grading system to determine tumor differentiation and prognosis. Treatment options depend on disease stage and include local therapies like surgery and radiation for early disease, hormone therapy for advanced or metastatic disease, and chemotherapy for hormone-refractory prostate cancer.
Locally advanced prostate cancer (LAPC) involves spread outside the prostate capsule or involvement of nearby structures. While no consensus exists on optimal treatment, combination therapy with radical prostatectomy (RP), radiation therapy (RT), and androgen deprivation (AD) provides the best outcomes. For selected patients with low-volume LAPC, RP alone may be sufficient, but extended pelvic lymph node dissection is important. Adjuvant or neoadjuvant RT and long-term AD after RP can improve local control and reduce recurrence rates. For patients unable to undergo surgery, RT with concurrent and adjuvant AD is the standard treatment and provides improved survival compared to monotherapy. Multimodal therapy increases side effects but provides superior outcomes over the
This document summarizes a randomized clinical trial comparing conventional and hypofractionated radiation therapy schedules for low-risk prostate cancer. The trial assigned patients to either 73.8 Gy in 41 fractions over 8.2 weeks (conventional) or 70 Gy in 28 fractions over 5.6 weeks (hypofractionated). The primary objective was to determine if the hypofractionated schedule was non-inferior to conventional in terms of efficacy. Over 1,000 patients were stratified by prostate-specific antigen level, Gleason score, and radiation modality before randomization. The trial was designed so that the biological effective doses of the two arms would be equal assuming an alpha-beta ratio of 10 for prostate cancer.
This document provides an overview of the history and current practices of prostate biopsy. It discusses the evolution from open transperineal biopsy to current standard of care transrectal ultrasound (TRUS)-guided biopsy. Recent studies have shown multiparametric MRI can improve detection of clinically significant cancer and potentially reduce unnecessary biopsies. The document reviews patient preparation, biopsy techniques including systematic and targeted biopsy approaches, complications, and post-biopsy management. It provides guidance on appropriate patient selection and when to consider additional investigation or repeat biopsy.
Prostate MRI provides a remarkable advancement in prostate cancer diagnosis and treatment by allowing doctors to accurately visualize, characterize, and stage prostate cancers. Prior methods like PSA screening and random biopsies were inaccurate and missed many aggressive cancers. Prostate MRI uses different parameters on T2-weighted, diffusion-weighted, and dynamic contrast enhanced images to identify cancer nodules, determine their likelihood of being aggressive, and stage the cancer. This allows targeted biopsies to diagnose aggressive cancers earlier for better treatment outcomes while avoiding overdiagnosis of less concerning cancers. Prostate MRI is now central to diagnosis, treatment planning and monitoring in prostate cancer care.
Basic information for discussion with a healthcare professional is provided here together with some background:
• An enlargement or the presence of tumors in the gland below a man’s bladder that produces fluid for semen ie, the prostate, may suggest benign prostatic hyperplasia (BPH) or prostate cancer
o Almost 8% of new cancer cases worldwide are attributed to this highly curable disease (proportion of patients surviving after 5 years = 98.9%)
o In the USA alone, prostate cancer is the most common non-skin cancer, diagnosed more often in African-American (1 in 5 cases) than white men (1 in 6 cases)
o Prostate cancer is strongly correlated with age, starting at about 50 years old and rising over the ensuing decades
o While debates over under- or over-treatment of prostate cancer continue, it is clear that management of the disease costs the USA an aggregate annual loss in productivity of $3.0 billion
o Moreover, prostate cancer is the third-leading cause of cancer-related deaths in the USA, mainly due to advanced or metastatic disease
This document discusses the role of various imaging modalities in detecting and staging prostate cancer, including transrectal ultrasound, MRI, MR spectroscopy, CT, nuclear medicine scans, and PET imaging. It provides details on what each modality can visualize, its accuracy for assessing the primary tumor and metastatic disease, and when it is recommended in prostate cancer evaluation, treatment planning, and follow-up.
MRI Guided Trans Rectal Ultrasound Biopsy: A Molecular Approach to Diagnosing...Apollo Hospitals
The purpose of this study is to assess the efficacy of second-look Trans- rectal Ultrasound guided biopsy by comparing the histopathological results obtained by Trans Rectal Ultra Sound guided extended sextant core biopsy of the prostate done before and after
localization of lesions using MRI & MRS done prior to the procedure.
This document discusses management of prostate cancer through different treatment modalities including active surveillance, radical prostatectomy, radiation therapy, and hormonal therapy. It provides treatment recommendations based on cancer stage and risk level as well as 5-year outcomes. For low risk prostate cancer, active surveillance, radical prostatectomy, or radiation therapy are recommended depending on life expectancy. Radiation therapy techniques like 3D-CRT, IMRT, and brachytherapy are covered. Dose escalation studies showing improved outcomes with higher radiation doses are also summarized.
The prostate is a gland that produces seminal fluid. Prostate cancer is the second most common cancer in men. The prostate has four zones - peripheral, transition, central and anterior fibromuscular. Prostate cancer usually arises in the peripheral zone and is typically an adenocarcinoma. Diagnosis involves a digital rectal exam, prostate-specific antigen testing, transrectal ultrasound of the prostate and biopsy. Staging involves evaluating if the cancer is organ-confined or has spread locally or metastasized. Treatment options depend on risk stratification and may include active surveillance, surgery, radiation therapy or hormone therapy.
This document discusses management strategies for localized prostate cancer, including active surveillance and radical prostatectomy. It notes that active surveillance involves delayed treatment if cancer progresses, allowing patients to avoid or delay unnecessary treatment. However, criteria for patient selection and treatment triggers require further definition and validation. Radical prostatectomy remains the gold standard for treating localized prostate cancer as it offers the possibility of cure while minimizing damage to surrounding tissues when performed skillfully. Innovations have led to improved preservation of urinary continence and erectile function with this procedure.
Chemoprevention aims to prevent prostate cancer using pharmaceutical agents. Some key points about chemoprevention of prostate cancer include:
- Finasteride and dutasteride, 5-alpha reductase inhibitors, have been shown to reduce the risk of prostate cancer, especially low-grade cancer, but may increase the risk of higher grade cancers.
- Selenium and vitamin E supplements have been studied but did not show a clear benefit and in some cases increased risk.
- Dietary factors like lycopene from tomatoes and phytoestrogens from soy products are thought to possibly reduce prostate cancer risk but evidence is limited.
- Larger randomized controlled trials of pharmaceutical agents like the PCPT and REDU
1) Short term ADT added to radiation therapy improved outcomes for intermediate risk prostate cancer, while long term ADT showed benefits in high risk disease based on multiple trials.
2) The AFFIRM trial showed that enzalutamide improved median survival to 18.4 months compared to 13.6 months for placebo in metastatic CRPC patients after docetaxel failure.
3) The COU-AA-301 trial found that abiraterone acetate plus prednisone improved median survival to 15.8 months compared to 11.2 months for placebo in metastatic CRPC patients after docetaxel failure.
This slide deck is about Prostate cancer. It is amongst the leading cause of cancer deaths in adult males. This slide deck will provide you with necessary information regarding the symptoms, risk, diagnosis, and possible treatment of prostate cancer. I hope the readers find this slide deck useful & informative
Advances in risk assessment, differential diagnosis between aggressive and non-aggressive tumors, and the development of novel/optimized treatment for advanced disease are discussed.
This slide deck is made available for patients/caregivers. It is not a substitute for seeking medical help. Please check original sources listed in the deck and consult your physician for the latest information and advice.
This document discusses the approach to localized prostate cancer. It begins by outlining the various treatment options available after diagnosis. It then defines localized prostate cancer and discusses how widespread PSA screening has led to earlier detection and improved survival rates. Risk stratification methods like the D'Amico and EAU systems are introduced. Counseling patients involves shared decision making considering cancer severity, life expectancy, expected functional outcomes, and risks. Treatment methods like active surveillance, surgery, radiation, and androgen deprivation are covered at a high level. Follow up for active surveillance involves periodic PSA, DRE, and biopsy to monitor for cancer progression.
This document provides information about cryotherapy as a treatment for prostate cancer from the Department of Urology at Govt Royapettah Hospital and Kilpauk Medical College in Chennai, India. It discusses the mechanisms of cryotherapy, how it is performed, outcomes, and complications. Cryotherapy uses freezing to induce coagulative necrosis in prostate cancer by damaging cells through mechanisms like protein denaturation and rupture of cell membranes from expanding ice crystals. It can be used to treat localized prostate cancer as an alternative to radical treatments like surgery or radiation. Common side effects include erectile dysfunction, urinary incontinence, and urethral sloughing.
Prostate cancer updates were presented. Key points include:
1) The Gleason score is used to assess tumor aggressiveness and has shifted to include higher scores over time.
2) Screening results do not support widespread mass screening, but early detection may be offered to informed men with baseline PSA testing at age 40 and screening intervals of 8 years if initial PSA is low.
3) For localized disease, treatment options include active surveillance, radical prostatectomy, or radiation therapy depending on risk level and life expectancy. Deferred treatment may be appropriate for many cases.
Background:To compare prostate cancer detection rates between transrectal ultrasound (TRUS) prostate biopsy and transperineal template prostate biopsy (TPTPB) in biopsy naïve men. TRUS biopsy is still regarded as gold standard for prostate cancer diagnosis. TPTPB has been shown to improve prostate cancer detection in men with rising PSA and previous negative TRUS biopsies. We carried out a prospective study performing both biopsies in the same group of men with a benign feeling digital rectal examination (DRE), PSA <20 ng ml(-1)><20 ng ml(-1). PSA appears to be better biomarker than previously thought.Prostate Cancer and Prostatic Disease advance online publication, 4 March 2014; doi:10.1038/pcan.2014.4.
Modern imaging techniques are improving the management of prostate cancer. Multiparametric MRI is now mandatory for locally advanced disease to assess extraprostatic extension and seminal vesicle involvement. While isotopic bone scans remain standard, newer techniques like sodium fluoride and choline PET scans show promise in detecting bone metastases and recurrence. Precise staging allows for personalized treatment selection between surgery, radiation, or systemic therapies and guides monitoring for progression.
This document provides an overview of prostate cancer including epidemiology, risk factors, screening recommendations, clinical presentation, diagnosis, staging and risk stratification. Some key points:
- Prostate cancer is the second most common cancer in men worldwide. Incidence and mortality increases with age.
- Risk factors include age, family history, metabolic syndrome, certain dietary factors and medications.
- Screening is recommended for men aged 55-69 with a PSA test and digital rectal exam. Screening intervals depend on PSA levels.
- Diagnosis involves PSA testing, digital rectal exam, and biopsy. Staging uses the Gleason score and TNM system to determine risk level and treatment options
This document discusses the management of intermediate and high risk prostate cancer. It begins by providing background on prostate cancer epidemiology and risk stratification. It then covers various treatment options including observation, active surveillance, radical prostatectomy, radiotherapy, and androgen deprivation therapy. Several studies comparing the efficacy of radiotherapy alone versus radiotherapy with short or long-term ADT are summarized. For intermediate risk prostate cancer, the document recommends 4-6 months of ADT with radiotherapy based on trial results. For high risk prostate cancer, 2-3 years of ADT with radiotherapy is recommended.
Locally advanced prostate cancer (LAPC) involves spread outside the prostate capsule or involvement of nearby structures. While no consensus exists on optimal treatment, combination therapy with radical prostatectomy (RP), radiation therapy (RT), and androgen deprivation (AD) provides the best outcomes. For selected patients with low-volume LAPC, RP alone may be sufficient, but extended pelvic lymph node dissection is important. Adjuvant or neoadjuvant RT and long-term AD after RP can improve local control and reduce recurrence rates. For patients unable to undergo surgery, RT with concurrent and adjuvant AD is the standard treatment and provides improved survival compared to monotherapy. Multimodal therapy increases side effects but provides superior outcomes over the
This document summarizes a randomized clinical trial comparing conventional and hypofractionated radiation therapy schedules for low-risk prostate cancer. The trial assigned patients to either 73.8 Gy in 41 fractions over 8.2 weeks (conventional) or 70 Gy in 28 fractions over 5.6 weeks (hypofractionated). The primary objective was to determine if the hypofractionated schedule was non-inferior to conventional in terms of efficacy. Over 1,000 patients were stratified by prostate-specific antigen level, Gleason score, and radiation modality before randomization. The trial was designed so that the biological effective doses of the two arms would be equal assuming an alpha-beta ratio of 10 for prostate cancer.
This document provides an overview of the history and current practices of prostate biopsy. It discusses the evolution from open transperineal biopsy to current standard of care transrectal ultrasound (TRUS)-guided biopsy. Recent studies have shown multiparametric MRI can improve detection of clinically significant cancer and potentially reduce unnecessary biopsies. The document reviews patient preparation, biopsy techniques including systematic and targeted biopsy approaches, complications, and post-biopsy management. It provides guidance on appropriate patient selection and when to consider additional investigation or repeat biopsy.
Prostate MRI provides a remarkable advancement in prostate cancer diagnosis and treatment by allowing doctors to accurately visualize, characterize, and stage prostate cancers. Prior methods like PSA screening and random biopsies were inaccurate and missed many aggressive cancers. Prostate MRI uses different parameters on T2-weighted, diffusion-weighted, and dynamic contrast enhanced images to identify cancer nodules, determine their likelihood of being aggressive, and stage the cancer. This allows targeted biopsies to diagnose aggressive cancers earlier for better treatment outcomes while avoiding overdiagnosis of less concerning cancers. Prostate MRI is now central to diagnosis, treatment planning and monitoring in prostate cancer care.
Basic information for discussion with a healthcare professional is provided here together with some background:
• An enlargement or the presence of tumors in the gland below a man’s bladder that produces fluid for semen ie, the prostate, may suggest benign prostatic hyperplasia (BPH) or prostate cancer
o Almost 8% of new cancer cases worldwide are attributed to this highly curable disease (proportion of patients surviving after 5 years = 98.9%)
o In the USA alone, prostate cancer is the most common non-skin cancer, diagnosed more often in African-American (1 in 5 cases) than white men (1 in 6 cases)
o Prostate cancer is strongly correlated with age, starting at about 50 years old and rising over the ensuing decades
o While debates over under- or over-treatment of prostate cancer continue, it is clear that management of the disease costs the USA an aggregate annual loss in productivity of $3.0 billion
o Moreover, prostate cancer is the third-leading cause of cancer-related deaths in the USA, mainly due to advanced or metastatic disease
This document discusses the role of various imaging modalities in detecting and staging prostate cancer, including transrectal ultrasound, MRI, MR spectroscopy, CT, nuclear medicine scans, and PET imaging. It provides details on what each modality can visualize, its accuracy for assessing the primary tumor and metastatic disease, and when it is recommended in prostate cancer evaluation, treatment planning, and follow-up.
MRI Guided Trans Rectal Ultrasound Biopsy: A Molecular Approach to Diagnosing...Apollo Hospitals
The purpose of this study is to assess the efficacy of second-look Trans- rectal Ultrasound guided biopsy by comparing the histopathological results obtained by Trans Rectal Ultra Sound guided extended sextant core biopsy of the prostate done before and after
localization of lesions using MRI & MRS done prior to the procedure.
This document discusses management of prostate cancer through different treatment modalities including active surveillance, radical prostatectomy, radiation therapy, and hormonal therapy. It provides treatment recommendations based on cancer stage and risk level as well as 5-year outcomes. For low risk prostate cancer, active surveillance, radical prostatectomy, or radiation therapy are recommended depending on life expectancy. Radiation therapy techniques like 3D-CRT, IMRT, and brachytherapy are covered. Dose escalation studies showing improved outcomes with higher radiation doses are also summarized.
The prostate is a gland that produces seminal fluid. Prostate cancer is the second most common cancer in men. The prostate has four zones - peripheral, transition, central and anterior fibromuscular. Prostate cancer usually arises in the peripheral zone and is typically an adenocarcinoma. Diagnosis involves a digital rectal exam, prostate-specific antigen testing, transrectal ultrasound of the prostate and biopsy. Staging involves evaluating if the cancer is organ-confined or has spread locally or metastasized. Treatment options depend on risk stratification and may include active surveillance, surgery, radiation therapy or hormone therapy.
This document discusses management strategies for localized prostate cancer, including active surveillance and radical prostatectomy. It notes that active surveillance involves delayed treatment if cancer progresses, allowing patients to avoid or delay unnecessary treatment. However, criteria for patient selection and treatment triggers require further definition and validation. Radical prostatectomy remains the gold standard for treating localized prostate cancer as it offers the possibility of cure while minimizing damage to surrounding tissues when performed skillfully. Innovations have led to improved preservation of urinary continence and erectile function with this procedure.
Chemoprevention aims to prevent prostate cancer using pharmaceutical agents. Some key points about chemoprevention of prostate cancer include:
- Finasteride and dutasteride, 5-alpha reductase inhibitors, have been shown to reduce the risk of prostate cancer, especially low-grade cancer, but may increase the risk of higher grade cancers.
- Selenium and vitamin E supplements have been studied but did not show a clear benefit and in some cases increased risk.
- Dietary factors like lycopene from tomatoes and phytoestrogens from soy products are thought to possibly reduce prostate cancer risk but evidence is limited.
- Larger randomized controlled trials of pharmaceutical agents like the PCPT and REDU
1) Short term ADT added to radiation therapy improved outcomes for intermediate risk prostate cancer, while long term ADT showed benefits in high risk disease based on multiple trials.
2) The AFFIRM trial showed that enzalutamide improved median survival to 18.4 months compared to 13.6 months for placebo in metastatic CRPC patients after docetaxel failure.
3) The COU-AA-301 trial found that abiraterone acetate plus prednisone improved median survival to 15.8 months compared to 11.2 months for placebo in metastatic CRPC patients after docetaxel failure.
This slide deck is about Prostate cancer. It is amongst the leading cause of cancer deaths in adult males. This slide deck will provide you with necessary information regarding the symptoms, risk, diagnosis, and possible treatment of prostate cancer. I hope the readers find this slide deck useful & informative
Advances in risk assessment, differential diagnosis between aggressive and non-aggressive tumors, and the development of novel/optimized treatment for advanced disease are discussed.
This slide deck is made available for patients/caregivers. It is not a substitute for seeking medical help. Please check original sources listed in the deck and consult your physician for the latest information and advice.
This document discusses the approach to localized prostate cancer. It begins by outlining the various treatment options available after diagnosis. It then defines localized prostate cancer and discusses how widespread PSA screening has led to earlier detection and improved survival rates. Risk stratification methods like the D'Amico and EAU systems are introduced. Counseling patients involves shared decision making considering cancer severity, life expectancy, expected functional outcomes, and risks. Treatment methods like active surveillance, surgery, radiation, and androgen deprivation are covered at a high level. Follow up for active surveillance involves periodic PSA, DRE, and biopsy to monitor for cancer progression.
This document provides information about cryotherapy as a treatment for prostate cancer from the Department of Urology at Govt Royapettah Hospital and Kilpauk Medical College in Chennai, India. It discusses the mechanisms of cryotherapy, how it is performed, outcomes, and complications. Cryotherapy uses freezing to induce coagulative necrosis in prostate cancer by damaging cells through mechanisms like protein denaturation and rupture of cell membranes from expanding ice crystals. It can be used to treat localized prostate cancer as an alternative to radical treatments like surgery or radiation. Common side effects include erectile dysfunction, urinary incontinence, and urethral sloughing.
Prostate cancer updates were presented. Key points include:
1) The Gleason score is used to assess tumor aggressiveness and has shifted to include higher scores over time.
2) Screening results do not support widespread mass screening, but early detection may be offered to informed men with baseline PSA testing at age 40 and screening intervals of 8 years if initial PSA is low.
3) For localized disease, treatment options include active surveillance, radical prostatectomy, or radiation therapy depending on risk level and life expectancy. Deferred treatment may be appropriate for many cases.
Background:To compare prostate cancer detection rates between transrectal ultrasound (TRUS) prostate biopsy and transperineal template prostate biopsy (TPTPB) in biopsy naïve men. TRUS biopsy is still regarded as gold standard for prostate cancer diagnosis. TPTPB has been shown to improve prostate cancer detection in men with rising PSA and previous negative TRUS biopsies. We carried out a prospective study performing both biopsies in the same group of men with a benign feeling digital rectal examination (DRE), PSA <20 ng ml(-1)><20 ng ml(-1). PSA appears to be better biomarker than previously thought.Prostate Cancer and Prostatic Disease advance online publication, 4 March 2014; doi:10.1038/pcan.2014.4.
Modern imaging techniques are improving the management of prostate cancer. Multiparametric MRI is now mandatory for locally advanced disease to assess extraprostatic extension and seminal vesicle involvement. While isotopic bone scans remain standard, newer techniques like sodium fluoride and choline PET scans show promise in detecting bone metastases and recurrence. Precise staging allows for personalized treatment selection between surgery, radiation, or systemic therapies and guides monitoring for progression.
This document provides an overview of prostate cancer including epidemiology, risk factors, screening recommendations, clinical presentation, diagnosis, staging and risk stratification. Some key points:
- Prostate cancer is the second most common cancer in men worldwide. Incidence and mortality increases with age.
- Risk factors include age, family history, metabolic syndrome, certain dietary factors and medications.
- Screening is recommended for men aged 55-69 with a PSA test and digital rectal exam. Screening intervals depend on PSA levels.
- Diagnosis involves PSA testing, digital rectal exam, and biopsy. Staging uses the Gleason score and TNM system to determine risk level and treatment options
This document discusses the management of intermediate and high risk prostate cancer. It begins by providing background on prostate cancer epidemiology and risk stratification. It then covers various treatment options including observation, active surveillance, radical prostatectomy, radiotherapy, and androgen deprivation therapy. Several studies comparing the efficacy of radiotherapy alone versus radiotherapy with short or long-term ADT are summarized. For intermediate risk prostate cancer, the document recommends 4-6 months of ADT with radiotherapy based on trial results. For high risk prostate cancer, 2-3 years of ADT with radiotherapy is recommended.
Mon 8-00 Prostate Cancer Screening in the Post-USPSTF Era_0.pptxRonitEnterprises
This document discusses prostate cancer screening and recommendations. It begins with a case presentation of a 54-year-old man before discussing the US Preventive Services Task Force recommendations against PSA screening. It then reviews the goals of cancer screening, basics of PSA testing and prostate cancer, impact of the Task Force, and ways to improve screening through risk stratification using newer biomarkers, imaging, and genetic profiling to avoid overdiagnosis while identifying high-risk cancers.
1) A study called PIVOT compared radical prostatectomy to observation in men with early stage prostate cancer over 12 years and found no significant difference in mortality. An extended follow up of PIVOT over 20 years still found no significant difference in all-cause or prostate cancer mortality between the two groups.
2) Absolute differences in mortality risk increased slightly over time but remained small, with less than a 6 percentage point difference in all-cause mortality and 4 percentage points for prostate cancer mortality. Surgery was associated with less disease progression but most progression was asymptomatic.
3) The study concludes that radical prostatectomy was not associated with significantly lower mortality compared to observation over 20 years. Death from prostate cancer was very uncommon
Reducing the Harm of Prostate Cancer Screening: Repeated Prostate-Specific Antigen Testing
Objective: To determine if repeating a prostate-specific antigen (PSA) test in men with an elevated PSA level is associated with a decreased risk of prostate biopsy and cancer diagnosis.
Conclusion: Routinely repeating a PSA test in patients with an elevated PSA level is independently associated with decreased risk of prostate biopsy and prostate cancer diagnosis. Men with an elevated PSA level should be given a repeated PSA test before proceeding to biopsy.
Prostate cancer is the second most common cancer in men worldwide. While early detection and treatment of localized prostate cancer can lead to many years of survival, the disease often progresses to an advanced or metastatic stage where it becomes resistant to hormonal therapies and has limited treatment options. New drugs like abiraterone and enzalutamide that target androgen signaling pathways have improved survival for men with metastatic castration-resistant prostate cancer, but optimal treatment sequencing remains unclear as the disease continues to evolve.
1. The document discusses the debate around prostate cancer screening in elderly men over age 65, with arguments on both sides.
2. Screening may detect cancers early that would not have progressed or caused harm in a man's lifetime given his life expectancy. However, screening also risks overdiagnosis and overtreatment of biologically unimportant cancers.
3. Guidelines in the US do not recommend routine screening for low-risk, elderly patients due to the scientific uncertainties around the balance of benefits and harms. Patient-clinician discussion is important to make informed, individual decisions.
1. The document discusses whether prostate cancer screening should be recommended for elderly men over age 65 given the high prevalence of prostate cancer but also the slow growing nature in many cases and short life expectancy.
2. While screening can detect cancer early, it also risks overdiagnosing biologically unimportant cancers and subjects men to potential harms of treatment without clear benefits due to their age.
3. Guidelines in the US have differing recommendations regarding screening older men, reflecting the ongoing debate around the balance of risks and benefits in this population.
This document summarizes the management of pancreatic carcinoma. It discusses the anatomy, epidemiology, risk factors, hereditary syndromes, pathophysiology including pre-cancerous lesions, types of pancreatic cancer, staging, prognostic factors, diagnostic techniques, treatment including surgery, chemotherapy, targeted therapy, radiotherapy and historical prospective studies. It provides a comprehensive overview of pancreatic carcinoma covering all relevant aspects of the disease.
Prostate cancer - Vincent Batista LemaireNiela Valdez
The document summarizes the PI-RADS (Prostate Imaging Reporting and Data System) guidelines for prostate imaging and reporting. It describes the goal of PI-RADS to standardize acquisition, interpretation, and reporting of prostate imaging globally. It also reviews techniques for prostate cancer screening and diagnosis including digital rectal exam, prostate-specific antigen testing, transrectal ultrasound biopsy, and multiparametric magnetic resonance imaging, and discusses the Gleason grading system for evaluating prostate cancer specimens.
Prostate cancer screening and early detection is an ongoing area of research and debate. While screening can detect prostate cancer earlier when it may be more treatable, it also leads to overdiagnosis and overtreatment. Several large clinical trials have had conflicting results on the benefits of prostate cancer screening. Guidelines from organizations also vary in their recommendations for screening. New biomarkers and imaging techniques are being studied to improve screening specificity and reduce unnecessary biopsies and treatment. Overall, the effectiveness of prostate cancer screening remains uncertain, and any decision to be screened requires informed discussion of risks and benefits.
Prostate cancer is the most common cancer in men. It arises from the epithelial cells of the prostate gland. Diagnosis is confirmed through biopsy of suspicious areas identified during digital rectal exam and imaging. Treatment options depend on disease stage and grade. For localized disease, options include watchful waiting, surgery, and radiation. Hormone therapy is the primary treatment for advanced or metastatic disease. Outcomes depend on clinical factors like stage and grade at diagnosis. Screening through PSA testing and DRE can facilitate early detection and improved prognosis.
Screening for Prostate cancer has had many different opinions and much research has been conducted in the last 20 years. In this presentation we will discuss the current guidelines for proper screening and gain more insight into men’s health.
MANAGEMENT OF BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY & RADIATION ...GAURAV NAHAR
This document discusses evaluation and management of prostate-specific antigen (PSA) recurrence after radical prostatectomy for localized prostate cancer. It defines PSA recurrence as a rising PSA level after surgery without clinical or radiographic evidence of disease. A PSA level of 0.2 ng/mL or higher is commonly used to define recurrence. Factors like preoperative PSA, Gleason score, and pathological stage can predict recurrence risk. While tests cannot reliably determine the site of recurrence at low PSA levels, treatment may involve observation, salvage radiation for presumed local recurrence, or hormone therapy for presumed metastases. The document outlines guidelines for these treatments and concludes that patients can be stratified into low, intermediate, and high risk groups
This document summarizes the management of prostate carcinoma. It discusses clinical features, risk stratification, treatment options including active surveillance, radical prostatectomy, radiation techniques, adjuvant and salvage radiation therapy, brachytherapy, and androgen deprivation therapy. Treatment is tailored based on risk factors, tumor characteristics, and patient factors. Image-guided radiation therapy helps ensure accurate targeting of the prostate. Dose escalation and addition of hormones improves outcomes for intermediate- and high-risk disease.
Pros and cons of prostate cancer screening by mungai ngugiKesho Conference
1) Prostate cancer screening can have both benefits and harms. The benefits include reducing mortality from prostate cancer by detecting it at an early stage, but screening also commonly results in false positives.
2) Common harms of screening include overdiagnosis where cancers are detected that would never have caused harm, false positives which can lead to invasive biopsies, and potential complications from treatment of screen-detected cancers including incontinence and erectile dysfunction.
3) Guidelines from organizations disagree on screening recommendations for men of different ages, but shared decision making is encouraged to weigh the benefits and harms based on individual risk factors and preferences.
Pros and cons of prostate cancer screening by mungai ngugiKesho Conference
1) Prostate cancer screening can have both benefits and harms. While screening may help reduce mortality by detecting cancer early, it can also lead to overdiagnosis and false positive results that cause unnecessary biopsies and treatments with side effects.
2) Guidelines from organizations like the U.S. Preventive Services Task Force and American Urological Association recommend shared decision making for men ages 55-69, as screening in this group balances a potential reduction in mortality with known harms. Screening is not routinely advised for men under 40 or over 70.
3) Trials show screening every 2 years may preserve benefits of screening while reducing overdiagnosis and false positives compared to annual screening. However,
Prostate cancer is the second most common cancer and sixth leading cause of cancer deaths among men worldwide. Incidence increases with age, peaking in men aged 75-79, and African American men have a higher risk than white men. Additional risk factors include family history, obesity, and diet high in fat and red meat. Prostate cancer typically spreads locally and via lymph nodes before potentially spreading to bone, with the lumbar spine being a common site of metastasis. Staging involves a PSA test, digital rectal exam, prostate biopsy, and imaging. Treatment depends on risk level, and may include active surveillance, surgery, radiation therapy, hormone therapy, or combinations of these.
This document discusses metastatic carcinoma of unknown primary (MCUP). Key points:
- MCUP accounts for 5-10% of cancer diagnoses and has a median survival of 6-12 months.
- Diagnostic workup includes clinical exam, imaging like CT scans, and pathology including immunohistochemistry to identify primary site or clinical syndrome in 30-80% of cases.
- Specific clinical syndromes like peritoneal carcinomatosis in women or squamous cell cancer in cervical lymph nodes can guide targeted treatment approaches with improved outcomes.
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxwalterHu5
In some case, your chronic prostatitis may be related to over-masturbation. Generally, natural medicine Diuretic and Anti-inflammatory Pill can help mee get a cure.
Travel vaccination in Manchester offers comprehensive immunization services for individuals planning international trips. Expert healthcare providers administer vaccines tailored to your destination, ensuring you stay protected against various diseases. Conveniently located clinics and flexible appointment options make it easy to get the necessary shots before your journey. Stay healthy and travel with confidence by getting vaccinated in Manchester. Visit us: www.nxhealthcare.co.uk
Osteoporosis - Definition , Evaluation and Management .pdfJim Jacob Roy
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.
- Video recording of this lecture in English language: https://youtu.be/Pt1nA32sdHQ
- Video recording of this lecture in Arabic language: https://youtu.be/uFdc9F0rlP0
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
DECLARATION OF HELSINKI - History and principlesanaghabharat01
This SlideShare presentation provides a comprehensive overview of the Declaration of Helsinki, a foundational document outlining ethical guidelines for conducting medical research involving human subjects.
Mercurius is named after the roman god mercurius, the god of trade and science. The planet mercurius is named after the same god. Mercurius is sometimes called hydrargyrum, means ‘watery silver’. Its shine and colour are very similar to silver, but mercury is a fluid at room temperatures. The name quick silver is a translation of hydrargyrum, where the word quick describes its tendency to scatter away in all directions.
The droplets have a tendency to conglomerate to one big mass, but on being shaken they fall apart into countless little droplets again. It is used to ignite explosives, like mercury fulminate, the explosive character is one of its general themes.
Tests for analysis of different pharmaceutical.pptx
Prostate cancer
1. Prostate Cancer
Introduction and Management
Prepared by:
Dr Ishwor Paudel
MS Resident, PAHS
Moderator:
Assoc. Prof. Dr. Sameer Shrestha
2. EPIDEMIOLOGY
• Most common noncutaneous malignancy in USA
– 19% of all cancers in Men
• Fifth leading cause of cancer deaths worldwide
• 63% cases diagnosed after 65 years
– Average age of death from prostate cancer – 77 years
• Only 3% of prostate cancer patient die of the
disease, most die with disease
3. Etiology
• Family and Genetic Influence
– Relative risk increases according to the number of
affected family members, their degree of
relatedness, and the age at which they were
affected
– Hereditary Pca : 6-7 year earlier disease onset
– Non hereditary : Germline mutation in genes
mediating DNA repair process (BRCA2; ATM)
• But aggressivenss and clinical course remains same
4. • Environment factors
– Metabolic syndromes increases risk of Cancer
– Obesity decreases risk of low grade Pca but increases
risk of high grade Pca
• Dietary factors
– Alcohol -Fried foods
– Dairy - Vitamin D
• 5-alpha-reductase inhibitors
–potential of preventing or delaying the
development of Pca
5. Histology
• Adenocarcinoma (more than 90%)
– Rarely Urothelial Carcinoma; Sarcomas
• Prostate epithelial cells stain positive for
Prostate Acid Phosphastase (PAP) & PSA
• Prostate cancer never has basal cell layer
• Most commonly located in peripheral zone
(70%); less commonly CZ(20%) and TZ(5-10%)
6. Symptoms and Signs
• Early stage: No symptoms
– Cancer is in the peripheral zone
• Locally advanced:
– Voiding/obstructive urinary
symptoms(hesistancy,intermittency, poor stream)
– Renal failure(due to ureteral obstruction)
– Hemospermia
– Decreased ejaculate volume
– Impotence (Rare)
8. Screening for prostate cancer
• Screening is done by
– Digital rectal examination (DRE)
– Prostate Specific Antigen (PSA) :
• Organ specific but disease specific ; increased on BPH,UTI,
Prostatitis
– Early PSA testing should be offered to well-informed
men at elevated risk of having PCa:
men > 50 years
men > 45 years and a family history of pca
men of African descent > 45 years
men carrying BRCA2 mutations > 40 years
9. • Offer a risk-adapted strategy (based on initial PSA level),
with follow-up intervals of 2 years for those initially at
risk:
men with a PSA level of > 1 ng/mL at 40 years of age
men with a PSA level of > 2 ng/mL at 60 years of age
• Postpone follow-up to 8 years in those not at risk.
• Stop early diagnosis of PCa based on life expectancy and
performance status; men who have a life-expectancy
of < 15 years are unlikely to benefit
10. Prostate Biopsy
• TRUS biopsy
– Standard of care when prostate biopsy is used to
identify prostate cancer
– Fine-needle aspiration biopsy is no longer
considered state-of-the-art in the diagnosis of Pca
– 8-12 cores from peripheral zones
– Also from suspicious areas
11. • When to biopsy?
– Suspicious DRE
– Abnormal PSA
• age and ethnicity adjusted
– Abnormal change in total PSA
• PSA velocity >=0.35 ng/ml/year (if PSA<4)
• PSA velocity >=0.75 ng/ml/year (if PSA >4)
• If PSA doesn’t decrease by 50% after 1 year of 5 ARI
– PSA density >=0.15
• PSA density = PSA/Volume of gland
12. • Re-biopsy after Initial negative biopsy
– Rising and/or persistently elevated PSA
– Atypical small acinar proliferation (40% ca risk)
– Extensive (multiple biopsy sites) with PIN (20%–
30% cancer risk)
– Suspicious lesion on prostate magnetic resonance
imaging
– Differentiate local recurrence versus systemic
disease with PSA recurrence after local ablative
therapy
13. • Gleason’s grade
– Architectural pattern of prostate glands as seen in
low power microscopy
– Architectural patterns are identified and assigned
a grade from 1 to 5
• 1 being the most differentiated and 5 being
undifferentiated
• Cytologic features play no role in the grade of the
tumor
14.
15. • Gleason score
– In original Gleason system, the most common and
second most common grades were combined
– In 2005 the Gleason system was updated and
modified with one change being that on biopsy
the most common and highest-grade patterns on
a given core were added
– If a tumor has only one histologic pattern, then for
uniformity, both patterns are assigned the same
grade
19. Risk Startification
EAU risk groups for biochemical recurrence of localised and locally advanced prostate
cancerEAU risk groups for biochemical recurrence of localised and locally advanced
20. Imagings in Prostate cancer diagnosis
• Transrectal ultrasound and ultrasound-based
techniques
– Grey-scale TRUS is not reliable at detecting Pca
– Diagnostic yield of additional biopsies performed
on hypoechoic lesions is negligible
– New sonographic modalities such as
sonoelastography, contrast-enhanced US or high-
resolution micro-ultrasound have given promising
preliminary findings; either alone or combined in
the so-called 'multiparametric US'
21. Multiparametric magnetic resonance
imaging
• Any functional form of imaging used to
supplement standard anatomical T1 and T2-
weighted imaging
– Dynamic contrast-enhanced (DCE) MRI and
diffusion-weighted imaging (DWI), including the
calculation of apparent diffusion co-efficient (ADC)
maps
– Achieves a positive predictive value for cancer of
98%, compared to the detection rate of 68% for
T2W MRI alone
22. Multiparametric MRI
• Good sensitivity for the detection and
localisation of ISUP grade > 2 cancers(91-94%)
• Less sensitive in identifying ISUP grade 1 Pca
– Identifies less than 30% of ISUP grade 1 cancers
smaller than 0.5cc
23. Guidelines for imaging in PCa
detection
• Do not use multiparametric magnetic resonance
imaging (mpMRI) as an initial screening tool
• In biopsy naïve patients
– Perform mpMRI before prostate biopsy
– When mpMRI is positive (i.e. PI-RADS > 3), combine
targeted and systematic biopsy
– When mpMRI is negative (i.e., PI-RADS < 2), and clinical
suspicion of prostate cancer is low, omit biopsy based on
shared decision making with the patient
24. • In patients with prior negative biopsy
– Perform mpMRI before prostate biopsy
– When mpMRI is positive (i.e. PI-RADS > 3),
perform targeted biopsy only
– When mpMRI is negative (i.e., PI-RADS < 2), and
clinical suspicion of prostate cancer is high,
perform systematic biopsy based on shared
shared decision making with the patient.
25. N-staging
• Abdominal CT and T1-T2-weighted MRI
indirectly assess nodal invasion by using LN
diameter and morphology
• Choline PET/CT-- low sensitivity
• Prostate-specific membrane antigen(PSMA)-
based PET/CT
– Improves the detectability of lesions
– specificity for prostate tissue
26. M-staging
• Bone scan
– 99mTc-Bone scan has been the most widely used
method for evaluating bone metastases of Pca
– Sensitivity and specificity of 79% and 82%
– Bone scanning should be performed in
symptomatic patients, independent of PSA level,
ISUP grade or clinical stage
29. Treatment modalities
Selection of treatment modalities depend upon:
1. Tumors potential aggressiveness
– Low , Intermittent and High risk
2. General health, Life expectancy and Quality
of life preferences
30. Watchful waiting
• Refers to conservative management for
patients deemed unsuitable for curative
treatment right from the outset
– Patients are 'watched' for the development of
local or systemic progression with (imminent)
disease-related complaints, at which stage they
are then treated palliatively according to their
symptoms, in order to maintain QoL
– Offered for aymptomatic patients with life
expectancy <10 years
31. Active Surveillance
• AS aims to avoid unnecessary treatment in
men with clinically localised PCa who do not
require immediate treatment
– But at the same time achieve the correct timing
for curative treatment in those who eventually do
– Patients remain under close surveillance through
structured surveillance programmes
– with regular follow-up, and curative treatment is
prompted by predefined thresholds
32. • Criteria for AS
– ISUP grade 1
– A clinical T1c or T2a
– PSA<10 ng/ml
– PSA density <0.15ng/ml/cc
• Can also be considered for men with favourable
ISUP 2 cancer
– (PSA < 10 ng/mL, clinical stage [< cT2a] and a low
number of positive cores)
– But Re-biopsy within 6 to 12 months to exclude
sampling error is mandatory
33. Active Surveillance -
Recommendations
– Patients with intraductal and cribiform histology
on biopsy should be excluded from AS
– Perform serum PSA assessment every 6 months.
– Perform DRE every 12 months.
– Repeat biopsy if there is evidence of PSA
progression, clinical progression on DRE or
radiological progression on mpMRI.
– During follow-up, if mpMRI is negative (i.e., PI-
RADS < 2) with low clinical suspicion of
progression , omit biopsy
34. Active surveillance Watchful waiting
Treatment intent Curative Palliative
Follow up Predefined schedule Patient-specific
Assessment/ Marker used DRE, PSA, Re-biopsy,
mpMRI
Not predefined
Life expectancy >10 yrs <10 yrs
Aim Minimise treatment-related
toxicity without
compromising survival
Minimise treatment related
toxicity
Comments Mainly Low risk patients Can apply to patients with
all stages
35. Active Treatment
• Radical Prostatectomy
– Goal is to eradication of cancer, while whenever
possible preserving pelvic organ function
– Involves removing entire prostate with its capsule
intact and seminal vesicles
– followed by undertaking vesico-urethral
anastomosis
– Can be open (perineal or retropubic), laparoscopic
or robotic
36. Lymph Node dissection
• Pelvic LN dissection
– excision of fibrofatty tissue & lymphatic tissue
between bifurcation of common iliac artery
superiorly to the femoral canal inferiorly and to pelvic
sidewall laterally, posteriorly to obturator nerve
• Extended LN dissection:
– conventional LN with posteriorly obturator vessels
and iliac vein
– Done in intermediate (if estimated risks of postitive
LN>5%) and high risk groups
37. EAU Recommendations for
Surgical treatment
• No surgical approach has clearly shown superiority
in terms of functional or oncological results
• Perform an extended LND template for optimal
staging when lymph node dissection required
• Do not perform nerve-sparing surgery when there is
a risk of ipsilateral extracapsular extension
• Do not offer neoadjuvant androgen deprivation
therapy before surgery
38. Radiotherapy
• Radical , adjuvant or palliative intent
• External beam radiotherapy
– Intensity modulated radiotherapy (IMRT), with or
without image guided radiotherapy (IGRT) is gold
standard for EBRT
– IMRT allows for dose distributions that have
higher conformality to the target via improved
shaping of dose within and around tissues,
thereby maximizing the dose of radiation that can
be safely delivered
39. Brachytherapy
• Brachytherapy (Greek word brakhus= “short”) is
the placement of radioactive sources into or near
tumors for therapeutic purposes
• Prostate brachytherapy is performed under
transrectal ultrasound guidance; seeds are placed
in a peripherally loaded pattern to minimize the
dose to the urethra(LDR)
• High-dose rate (HDR) brachytherapy uses a
radioactive source temporarily introduced into
the prostate to deliver radiation
40. • Eligibilty criteria for LDR Brachytherapy as
monotherapy
– Stage cT1b-T2a N0,M0
– ISUP grade 1 with < 50% of biopsy cores involved with
cancer or ISUP grade 2 with < 33% of biopsy cores
involved with cancer
– An initial PSA level of < 10 ng/mL
– a prostate volume of < 50 cm3
– an International Prostatic Symptom Score (IPSS) < 12
– maximal flow rate > 15 mL/min on urinary flow test
41. Recommendations for radiotherapy
• Offer IMRT or volumetric arc external beam radiotherapy ( VMAT)
for definitive treatment of prostatic carcinoma by EBRT
• Offer moderate hypofractionation (HFX) with IMRT/VMAT
including image guided radiation therapy to the prostate, to
carefully selected patients with localised diseases
• Ensure that moderate HFX adheres to radiotherapy protocols
from trial with equilibrium outcome and toxicity i.e 60Gy/20
fraction in 4 weeks or 70Gy/28 fraction in 6 weeks
42. Androgen deprivation therapy
• Depriving male sex hormones (testosterone ,
androgens) which are critical to Pca growth
– Normalization of PSA<4ng/ml- 60-70%
– Tumor mass decreases by half or more in 30-50%
– Improvement in symptoms (bone pain, urinary
obstruction) – 60%
44. Treatment of low-risk disease
• Active surveillance
• Active treatment
Offer surgery and radiotherapy as alternatives to AS to patients
suitable for such treatments
Do not perform a PLND
• Radiotherapeutic treatment
– Offer low-dose rate brachytherapy to patients with low-risk PCa,
without a previous TURP, with a good IPSS and a prostate
volume < 50 mL.
– intensity-modulated radiation therapy with a total dose of 74-80
Gy or moderate hypofractionation (60 Gy/20 fx in 4 weeks or 70
Gy/28 fx in 6 w
45. Treatment of intermediate-risk disease
• Active surveillance
Offer AS to highly selected patients accepting the
potential increased risk of further metastases.
• Radical prostatectomy
– With intermediate-risk disease and a life expectancy
of > 10 years.
– Perform an ePLND in intermediate-risk disease if the
estimated risk for positive lymph nodes exceeds 5%.
46. • Radiotherapeutic treatment
Low-dose rate brachytherapy to selected patients
patients without a previous TURP, with a good Ipss
and a prostate volume < 50 mL.
External-beam radiation therapy (EBRT): use a total
dose of 76-78 Gy or moderate hypofractionation
(60 Gy/20 fx In 4 weeks or 70 Gy/28 fx in 6 weeks),
combine with short-term neoadjuvant plus
concomitant androgen deprivation therapy (ADT) (4
to 6 months).
47. Treatment of high-risk localised disease
• Radical Prostatectomy (RP)
– Perform an ePLND in high-risk PCa.
• Radiotherapeutic treatment
– External-beam radiation therapy (EBRT) with 76-
78 Gy in combination with long-term androgen
deprivation therapy (ADT) (2 to 3 years).
48. Radical treatment of locally-
advanced disease
• Radical Prostatectomy (RP)
– highly selected patients with cT3b-T4 N0 or any cN1
only as part of multi-modal therapy.
– Perform an ePLND in high-risk PCa.
• Radiotherapeutic treatments
– Patients with locally advanced cN0 disease, offer
radiotherapy in combination with long-term androgen
deprivation therapy (ADT) for at least 2 year
49. • Therapeutic options outside surgery and
radiotherapy
• offer ADT monotherapy for
patients unwilling or unable to receive any form of
local treatment
PSA-doubling time < 12 months
PSA > 50 ng/mL, a poorly-differentiated tumour or
troublesome local disease-related symptoms.
50. Adjuvant treatment after radical prostatectomy
• Immediate (adjuvant) post-operative external
irradiation after RP (cN0 or pN0)-Highly selected
individual
• PN0 Patient:
– Do not use androgen deprivation therapy
• PN+ after eLND: offer ADT alone or with Radiotherapy
• Expectant Management:
< 2 nodes with microscopic
involvement
PSA < 0.1 ng/mL
Absence of extranodal extension.
51. Persistent PSA after radical
prostatectomy
• Post-RP PSA of > 0.1 ng/mL within 4 to 8 weeks of
surgery
• May result from persistent local disease, pre-existing
metastases or residual benign prostate tissue.
• PSMA PET scan to men with a persistent PSA > 0.2
ng/mL to exclude metastatic disease.
• Salvage radiotherapy and Additional hormonal
therapy used to treat men with no evidence of
metastatic disease
52. Guidelines for imaging in patients with
biochemical recurrence
• Prostate-specific antigen (PSA) recurrence
after radical prostatectomy
Perform PSMA PET-CT if the PSA level is > 0.2
ng/mL and if the results will influence subsequent
treatment decisions
If PSMA PET-CT not available and PSA > 1 ng/mL,
perform fluciclovine PET/CT or choline PET/CT
53. • PSA recurrence after radiotherapy
Any any PSA increase > 2 ng/mL higher than the PSA
nadir value, regardless of the serum concentration of
the nadir
Mp MRI to localise abnormal areas and guide biopsies
in patients fit for local salvage therapy.
Perform PSMA PET/CT (if available) or fluciclovine
PET/CT or choline PET/CT in patients fit for curative
salvage treatment
54. Follow up
• Asymptomatic patients
At 3, 6 and 12 months after treatment, then every 6
months until 3 years, and then annually.
Specific history and serum PSA measurement
• At recurrence, only perform imaging to detect
local recurrence
• Offer bone scan and other imaging if biochemical
reccurence and symptoms of disease progression
55. Treatment of Metastatic prostate
cancer
• Recommendations include
– Immediate systemic treatment with androgen
deprivation therapy (ADT) to M1 symptomatic
patients
• Palliate symptoms
• Reduce the risk for potentially serious sequelae of
advanced disease (spinal cord compression,
pathological fractures, ureteral obstruction)
– Surgery and/or local radiotherapy to any patient
with M1 disease and evidence of impending
complications
56. • Do not offer AR antagonists monotherapy to
patients with M1 disease
• Offer ADT combined with chemotherapy
(docetaxel) to patients whose first
presentation is M1 disease and who are fit for
docetaxel
57. • Offer ADT combined with abiraterone acetate
plus prednisone or apalutamide or
enzalutamide for M1
• Offer ADT combined with prostate
radiotherapy to M1 withlow volume of
disease by CHAARTED criteria
58. Treatment: Castration-resistant PCa
(CRPC)
• Definition:
– Castrate serum testosterone < 50 ng/dL or 1.7
nmol/L plus either:
• Biochemical progression: Three consecutive rises in PSA
at least one week apart resulting in two 50% increases
over the nadir, and a PSA > 2 ng/mL
Or
• Radiological progression: The appearance of new
lesions: either two or more new bone lesions on bone
scan or a soft tissue
59. Non-metastatic castrate-resistant
disease
• Offer apalutamide, darolutamide or
enzalutamide to patients with M0 CRPC and a
high risk of developing metastasis (PSA-
DT < 10 months) to prolong time to
metastases
60. Metastatic Castrate resistant PCa
• Chemotherapeutic agents
– Docetaxel 75mg every 3 weeks
– If progression;2nd generation taxel (cabazitaxel)
• Next gen hormonal therapy
– Abiraterone (used with prednisolone or
Eplerenone and LHRH agonist/antagonist)
61. • Androgen receptor modulator
– Enzalutamide (lacks requirement of concurrent
corticosteroid administration)
• Immunotherapy
– Sipuleucel-T (indicated for asymptomatic
/minimally symptomatic mCRPC without visceral
mets)
• Pembrolizumab
– mCRPC with MSI-high &/or MMR deficient patient
65. The androgen-signaling axis and
its inhibitors. Testicular androgen
synthesis is regulated by the
gonadotropin-releasing
hormone (GnRH)-LH axis,
whereas adrenal androgen
synthesis is regulated by the
corticotrophin-releasing
hormone (CRH)-ACTH axis. GnRH
agonists and corticosteroids
inhibit stimulation of the testes
and adrenals, respectively.
Abiraterone inhibits CYP17, a
critical enzyme in androgen
synthesis. Bicalutamide,
flutamide, and nilutamide
competitively inhibit the binding
of androgens to androgen
receptors; enzalutamide also
blocks the translocation
of the ligand bound AR complex to the nucleus and from binding to DNA. DHEA,
dehydroepiandrosterone; DHEA-S, dehydroepiandrosterone sulphate; DHT,
dihydrotestosterone; AR, androgen receptor; ARE, androgen-response element.
66.
67. Side-effects of hormonal therapy
• Castration
• Loss of libido
• Erectile dysfunction
• Hot flashes (55-80% duringADT)
• Gynaecomastia and breast pain Increase in body fat
• Decrease in bone mineral density
• Osteoporosis
• Muscle wasting
• Anaemia (severe in 13% CAB)
• Cognitive decline
• Oestrogens
• Cardiovascular toxic effects (AMI, CHF, CVA, DVT, pulmonary embolism)
• LHRH agonists
• Flare phenomenon due to initial rise of testosterone
• Might worsen symptoms
• Costly
68. Enzalutamide:
• Anovel anti-androgen that blocks AR binding, nuclear
translocation and transcription.
• Enzalutamide is used as a once-daily oral treatment.
• AFFIRM study in 2012 randomized 1,199 patients with metastatic
CRPC in a 2/1 fashion between enzalutamide or placebo. (The
patients had progressed after docetaxel treatment).
• After a median follow-up of 14.4 months, the median survival in
the enzalutamide group was 18.4 months compared to 13.6 months
in the placebo arm (HR: 0.63, p < 0.001). This led to the
recommendation that the study be halted and unblinded.
• The benefit was observed irrespective of age, baseline pain
intensity, and type of progression.
69. Abiraterone Acetate
• CYP17 inhibitor.
• It is used once daily combined with prednisone twice daily (10 mg/ day).
• large phase III COU-AA-301 trial used a total of 1,195 patients with metastatic
CRPC were randomised in a 1/1 fashion between abiraterone acetate or placebo,
In patients with progressive disease after docetaxel therapy the median survival
in the abiraterone group was 15.8 months compared to 11.2 months in the placebo
arm (HR: 0.74, p < 0.001).
• The benefit was observed irrespective of age, baseline pain intensity, and type of
progression.
• most common grade 3/4 side effects did not differ significantly but
mineralocorticoid-related side effects were more frequent in the abiraterone
group, mainly grade 1/2 (fluid retention, oedema or hypokalaemia).
• As of today, the choice between third-line hormonal treatment
(using enzalutamide or abiraterone) or second line
chemotherapy (cabazitaxel) remains unclear with no clear
decision-making findings published.
70. • Bone-seeking radiopharmaceuticals (samarium-153-
EDTMP, strontium-89):
Three radiopharmaceuticals are currently FDA-approved for the
palliative treatment of painful bone metastases
1. phosphorus-32 2.strontium-89 3.samarium-153-EDTMP.
Myelosuppression is the predominate toxicity associated with all of the bone
seeking radioisotopes.
71. Follow Up
Schedule Frequency
First follow up 4-6 weeks after RT
0-1 years Every 3-4 months
2-5 years Every 6 months
5+ years Annually
Examination
History & Physical Complete History & Physical
Examination Examination
Annual DRE
Laboratory Tests PSA every 6-12 months for 5
years and then annually
Imaging Studies Based on clinical indication
only
Editor's Notes
however, men with familial prostate cancer, on average, die at an earlier age than men without a family history of prostate cancer
use of PSA as a screening test has had the greatest impact on the incidence and potentially mortality of prostate cancer worldwide. Since the introduction of the PSA test, lifetime risk for prostate cancer in the United States has nearly doubled from 7.8% to 12.9%, and the risk for dying from this disease has decreased from 3% to 2.5%
Prostate basal layer stain positive for HMWK(high molecular weight cytokeratin)
Since spread to umbar vertebrae and long bones
Assymetrical or b/l edema with big LN in inguinal area, so DRE n PSA
Done if life expectancy is greater than 10 years; - NNS – 781; NNT27
Men at elevated risk for having prostate cancer are those older than 50 years of age; those who have a family history of prostate cancer and are older than 45 years of age or African-American; or those with a PSA level greater than 1 ng/ mL at 40 years of age and greater than 2 ng/mL at 60 years of ag
Seventy percent of serum PSA is bound to three proteins: α2-macroglobulin, α1-protease inhibitor, and α1- antichymotrypsin. Patients with prostate cancer have a higher fraction of circulating PSA bound to these proteins, that is, they have a lower free PSA.
Historically, many clinicians would recommend prostate biopsy once a patient’s serum PSA level rose above 4.0 ng/mL. Subsequent data from the Prostate Cancer Prevention Trial demonstrated that there is no safe PSA threshold that can rule out prostate cancer in any age range
Current threshold being >2.5-3 ng/ml
American College of Preventive Medicine determined there is insufficient evidence to recommend routine population screening with PSA and DRE (Lim et al., 2008) and suggests that men should be given information about benefits and harms to make an informed decision. The American Cancer Society recommends that men with at least a 10-year life expectancy should have an opportunity to make an informed decision with their health care provider about prostate cancer screening beginning at 50 years of age for average-risk men and before 50 years of age for groups at higher risk (
Extensive >3; prostate intraepithelial neoplasm
Positive urinary PCA3 or other newer genomic tests such as ConfirmMDxa methylation assay
Cytologic features play no role in the grade of the tumor
hese techniques are still limited by lack of standardisation, lack of large-scale evaluation and unclear results in transition zones
ensitivity (16%) makes spectroscopy poor for lesion detection, and although its excellent specificity (100%) can improve lesion characterisation, the overall benefit is comparatively small
the pooled sensitivity and specificity were 77% and 97%, respectively
68Ga- or 18F-labelled prostate-specific membrane antigen (PSMA) positron-emission tomography (PET)/CT is increasingly used, because it provides excellent contrast-to-noise ratio, thereby improving the detectability of lesions.
survival are both inversely related to the pathologic stage of disease.
• Pathologic criteria that predict prognosis after radical prostatectomy are tumor grade, surgical margin status, presence of extracapsular disease, seminal vesicle invasion, and pelvic lymph node involvement
indicative of potentially life-threatening disease which is still potentially curable, while considering individual life expectancy.
Definitely men with pelvic node involvement fare poorly. So controversy persists about PND.
Bowel and bladder preparation is done and radiotherapy
High dose rate brachytherapy uses a radioactive source temporarily introduced into prostate to deliver radiation..single or multiple fractions and is combined with EBRT of at least 45 Gy
Low-dose rate brachytherapy can be combined with EBRT in intermediate-/high-risk patients
Moderate HFX is defined as RT with 2.5-4 Gy/fx
VMAT has shorter treatment times, 2-3min..both techniques allow for complex distribution of dose to be delivered within treatment field and provide concave isodense curve,,useful for sparing the rectum
Common toxicities included dysuria, urinary frequency, urinary retention, haematuria, diarrhoea, rectal bleeding and proctitis [537]. In addition, general side-effects such as fatigue are common. It should be noted that the incidence of acute side-effects is greater than that of late effects (see Section 8.2.2.1), implying that most acute effects resolve.
Androgen deprivation can be achieved by either suppressing the secretion of testicular androgens or inhibiting the action of circulating androgens at the level of their receptor
two methods can be combined to achieve what has been known as complete (or maximal or total) androgen blockade (CAB) using the old-fashioned anti-androgens
Castration level testosterone <20ng/ml (1nmol/L)..traditional (<50nmol/L)
Bilateral orchiectomy, or subcapsular pulpectomy, is still considered the primary treatment modality for ADT. It is a simple, cheap and virtually complication-free surgical procedure. It is easily performed under local anaesthesia and it is the quickest way to achieve a castration level, which is usually reached within less than twelve hour
Degarelix LHRH antagonists ; 240mg in first month followed by monthly injections of 80mg..castrate level @day3
LHRH agonists ; available in depot form 1-2-3-6 monthly or yearly but assoc with flare up day2,3-lasts for 1 week
Increased bone pain , acute BOO, obstructive renal failure, spinal cord compressionand cardiovascular death due to hypercoagulation status esp in high volume symptomatic bony disease
a PSA > 0.4 ng/mL and rising
Offer luteinising hormone-releasing hormone (LHRH) antagonists, especially to patients with an impending spinal cord compression or bladder outlet obstruction.
Previously bi-calutamide and ketoconazole was 1st line
And LHRH agonist/antagonist
standard first-line chemotherapy is docetaxel 75 mg/m2, 3-weekly doses combined with prednisone 5 mg twice a day (BID), up to 10 cycle
Zoledronate 4mg Iv repeated @ 4 weeks interval for several months with oral calcium 1000mg/day and vit D 800units/day
Radium-223
The only bone-specific drug that is associated with a survival benefit is the α-emitter radium-223.
RANK ligand inhibitors
Denosumab is a fully human monoclonal antibody directed against RANKL (receptor activator of nuclear factor kappa-B ligand), a key mediator of osteoclast formation, function, and survival. In M0 CRPC, denosumab has been associated with increased bone-metastasis-free survival compared to placebo